HC Surgical Specialists (1B1) is a SG-listed Healthcare company in Medical - Diagnostics & Research with a market capitalization of S$61M, trading at S$0.40 on the SES. This SniperIQ fundamentals page covers HC Surgical Specialists's valuation (P/E 6.7x, P/B 2.6x), profitability (net margin 47.2%), revenue (S
9M in FY2024), balance-sheet quality, and AI signal context — from live market data, research only.
Market CapS$61M
P/E (TTM)6.7x
Net Margin47.2%
Revenue (FY24)S
9M
Full research coverage
8-Quarter Revenue & Margin Trend
Debt Maturity & Coverage
Peer Valuation Comparison
Free Cash Flow & Owner Earnings
AI Signal + Institutional Flow
DCF Valuation Model
Frequently Asked Questions
What is HC Surgical Specialists's market cap?
HC Surgical Specialists (1B1) has a market capitalization of approximately S$61M, trading at S$0.40 on the SES. Market cap moves with the live share price.
What is HC Surgical Specialists's P/E ratio?
HC Surgical Specialists's trailing twelve-month P/E ratio is 6.7x, with a price-to-book (P/B) of 2.6x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is HC Surgical Specialists?
HC Surgical Specialists runs a net profit margin of 47.2%, a gross margin of 44.3%, and an operating margin of 44.2%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does HC Surgical Specialists generate?
HC Surgical Specialists reported revenue of S
9M for fiscal year 2024, with net income of S$8M and earnings per share (EPS) of 0.0549. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does HC Surgical Specialists pay a dividend?
HC Surgical Specialists offers a trailing dividend yield of about 5.3%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is HC Surgical Specialists financially healthy?
HC Surgical Specialists carries a debt-to-equity ratio of 0.10x and a current ratio of 1.96x, with a market beta of -0.16. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is HC Surgical Specialists a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For HC Surgical Specialists (1B1) the key facts are: market cap S$61M, P/E 6.7x, revenue S
9M, 52-week range 0.31-0.4. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track HC Surgical Specialists's full fundamentals live
Get HC Surgical Specialists's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.